Aldeyra Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview

Aldeyra Therapeutics

01/08/2023 19:37

* Aldeyra Therapeutics Inc  ALDX.OQ   ALDX.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 3 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Aldeyra
Therapeutics Inc
is for a loss of 31 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aldeyra
Therapeutics Inc is $17.5​, above​ its last closing price
of $8.12. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.29       -0.29      -0.27     Beat    7.4
 Dec. 31 2023  -0.29       -0.31      -0.22     Beat    29.7
 Sep. 30 2022  -0.33       -0.34      -0.25     Beat    27.3​
 Jun. 30 2022  -0.32       -0.31      -0.30     Beat    3.5
 ​​Mar.        -0.32       -0.32      -0.29     Beat    8
 31 2022                                                
 Dec. 31 2021  -0.27       -0.28      -0.27     Beat    4.3​
 Sep. 30 2021  -0.25       -0.26      -0.27     Missed  -2.8
 Jun. 30 2021  -0.23       -0.24      -0.28     Missed  -15.8
 This summary was machine generated August 1 at 18:37 GMT.  All
figures in US dollars  unless otherwise stated